Home » Topics » Regulatory » NMPA

NMPA
RSS

Fosun Pharma reports Chinese IND application for FCN-437c

July 19, 2017

CStone cleared to begin clinical trials of CS-1001 in China

July 18, 2017

China FDA accepts fruquintinib NDA for advanced colorectal cancer

June 12, 2017

Tagrisso approved in China for NSCLC

March 27, 2017

WuXi-MedImmune cleared to conduct phase I studies of WBP-216 in China

Jan. 19, 2017

U.S. and China IND clearances for Ascentage's APG-1252

Dec. 28, 2016

CFDA grants approval for clinical trials of fadanafil

Dec. 16, 2016

CFDA accepts CStone Pharmaceuticals' IND for anti-PD-L1 monoclonal antibody

Oct. 21, 2016

BeiGene cleared to conduct clinical trials of BGB-A317 in China

Sep. 12, 2016

Chinese clinical trial authorization for TaiGen's furaprevir

Aug. 19, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...